	US 12,478,674 B2
	Ipilimumab variants with enhanced specificity for binding at low pH
Peter Sung Keun Lee, Millbrae, CA (US); Pavel Strop, San Mateo, CA (US); Arvind Rajpal, San Francisco, CA (US); Olafur S. Gudmundsson, West Windsor, NJ (US); and Pradyot Nandi, Haskell, NJ (US)
Assigned to BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Appl. No. 17/604,711
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
PCT Filed Apr. 16, 2020, PCT No. PCT/US2020/028402 § 371(c)(1), (2) Date Oct. 18, 2021, PCT Pub. No. WO2020/214748, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/835,794, filed on Apr. 18, 2019.
Prior Publication US 2022/0193237 A1, Jun. 23, 2022
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39575 (2013.01) [A61K 39/39591 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01)]

10 Claims

1. An anti-human CTLA-4 antibody, or antigen binding fragment thereof, that has an acidic pH binding preference (APBP) for binding at acidic pH compared to binding at neutral pH, comprising the heavy chain variable region sequence of residues 1-118 of SEQ ID NO: 14 and the light chain variable region sequence of residues 1-108 of SEQ ID NO: 28.